Rollins Inc. ROL
Rollins is the 'Cockroach' of activism: SEC settlement, auditor swap, family insider sales, and a 27x EBITDA multiple set up 30-40% downside as Rentokil/Terminix and PE roll-ups erode the moat.
Thesis
Spruce Point argues that Rollins, the S&P 500 owner of Orkin, is a strong sell with 30-40% downside to $21.75-$25.40 per share. The thesis bundles forensic accounting concerns — a 2022 SEC settlement for 'improper earnings management,' a 2023 auditor change, and recent 10-K revisions — with a deteriorating competitive backdrop in which Rentokil's acquisition of Terminix has created a new global leader and roughly $300bn of private equity capital is bidding up tuck-in M&A. Margins face headwinds from churn (~25%), digital marketing inflation, fleet refinancing at 7%+ rates, and rising auto-accident claims. Meanwhile the Rollins family unloaded $1.5bn of stock at an 8% discount to market while management adopted 10b5-1 selling plans and revolver capacity ballooned from $175m to $1bn. At 27x EBITDA versus 18x precedent transactions, the multiple should compress materially.
SCQA
Rollins is an S&P 500 pest-control operator (Orkin brand) trading at ~27x EBITDA on the narrative of recurring revenue, pricing power, and disciplined M&A in a fragmented essential-services industry.
An SEC 'improper earnings management' settlement, an auditor change, restated 10-K, levered Fox Pest acquisition with decelerating growth, and intensifying competition from Rentokil/Terminix plus $300bn of PE capital signal both accounting risk and a fading moat.
Sell ROL: re-rate the multiple to reflect peer M&A precedents (~18x EBITDA) and treat accelerating Rollins-family stock sales ($1.5bn at $35) and management 10b5-1 plans as the insider exit signal.
30-40% downside to $21.75-$25.40 per share, derived from 4.0x sales / 18x EBITDA on 2024E numbers, implying $10.4-$13.0bn of equity value vs. ~$18bn today.
The three reasons
- 1
Rollins embodies the 'Cockroach Theory': SEC settlement, auditor change, 10-K revisions — more bad news to come
- 2
Rentokil/Terminix merger and $300bn of PE capital are eroding Rollins' moat and pricing power
- 3
Rollins family just sold $1.5bn at an 8% discount while CEO/CFO adopted 10b5-1 selling plans
Primary demands
- Sell Rollins stock — Strong Sell rating with 30-40% downside
- Reassess Rollins' premium multiple given competitive intensification from Rentokil/Terminix and PE roll-ups
- Scrutinize Rollins' financial reporting given the recent SEC 'improper earnings management' settlement, auditor change, and 10-K revisions
- Follow the Rollins family's accelerating insider stock sales ($1.5bn at $35/share, 8% discount to market) as a sell signal
KPIs cited
Pattern membership
Precedents cited
- Generac (GNRC) — Spruce Point short, -60% post-report
- Mettler-Toledo (MTD) — Spruce Point short, -22% post-report
- A.O. Smith (AOS) — Spruce Point short, -30% post-report
- Rentokil/Terminix merger (Dec 2021)
- EQT/Anticimex transaction (June 2021)
Composition what's on the 89 slides
Slide gallery ·
Notes
Cover slide is a striking conceptual photo (rats, roaches, flies on a kitchen counter) tied to the 'Cockroach Theory of Investing' frame — unusually editorial for a short report and worth preserving as a swipe specimen. Two-column 'Promoter / Market View vs. Spruce Point Reality' tables (pp. 8-9) are a clean rhetorical pattern. Track-record slide (p.3) opens by anchoring credibility on Generac/Mettler/AOS prior shorts. Author not named on cover; Spruce Point is led by founder Ben Axler but the document attributes only to the firm. Stake size not disclosed (typical for short reports — they disclose 'short position' without quantifying).